Specify a stock or a cryptocurrency in the search bar to get a summary
HEMOSTEMIX INC.
HMTXFHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Address: 707-7th Avenue SW, Calgary, AB, Canada, T2P 3H6
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HMTXF
Dividend Analytics HMTXF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HMTXF
Stock Valuation HMTXF
Financials HMTXF
Results | 2019 | Dynamics |